This is a published notice on the Find a Tender service: <a href="https://www.find-tender.service.gov.uk/Notice/014956-2025">https://www.find-tender.service.gov.uk/Notice/014956-2025</a>

Award

# NP34925a Hepatitis B immunoglobulin intramuscular use (IM)

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

F15: Voluntary ex ante transparency notice

Notice identifier: 2025/S 000-014956

Procurement identifier (OCID): ocds-h6vhtk-05027f

Published 14 April 2025, 1:30pm

# Section I: Contracting authority/entity

## I.1) Name and addresses

The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS)

1 South Gyle Crescent

Edinburgh

**EH12 9EB** 

#### **Email**

holly.bryce@nhs.scot

#### **Telephone**

+44 1312756000

#### Country

United Kingdom

#### **NUTS** code

UKM - Scotland

#### Internet address(es)

Main address

http://www.nss.nhs.scot/browse/procurement-and-logistics

Buyer's address

 $\underline{https://www.publiccontractsscotland.gov.uk/search/Search\_AuthProfile.aspx?ID=AA1188}\\ \underline{3}$ 

# I.4) Type of the contracting authority

Body governed by public law

## I.5) Main activity

Health

# **Section II: Object**

# II.1) Scope of the procurement

#### II.1.1) Title

NP34925a Hepatitis B immunoglobulin intramuscular use (IM)

#### II.1.2) Main CPV code

• 33600000 - Pharmaceutical products

#### II.1.3) Type of contract

**Supplies** 

#### II.1.4) Short description

Supply of Hepatitis B immunoglobulin intramuscular use (IM) to NHS Scotland.

#### II.1.6) Information about lots

This contract is divided into lots: No

#### II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £343,908

## II.2) Description

#### II.2.3) Place of performance

**NUTS** codes

· UKM - Scotland

Main site or place of performance

The Scottish National Blood Transfusion Service, Edinburgh (SNBTS).

OR

Upon request: designated delivery points throughout Scotland for use by Participating Authorities.

#### II.2.4) Description of the procurement

The Framework Agreement is for the supply of Hepatitis B immunoglobulin intramuscular use (IM) to NHS Scotland. The Framework Agreement has been awarded as a single supplier framework agreement to one (1) Framework Participant.

#### II.2.11) Information about options

Options: No

#### II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

# Section IV. Procedure

# **IV.1) Description**

#### IV.1.1) Type of procedure

Negotiated without a prior call for competition

- The works, supplies or services can be provided only by a particular economic operator for the following reason:
  - o absence of competition for technical reasons

#### Explanation:

Although Hepatitis B immunoglobulin intramuscular use (IM) has lost patent protection there is no known generic competition in the UK marketplace due to the difficulties in replicating the manufacturing process, in line with Regulation 33(1)(b)(ii) of the Public Contracts (Scotland) Regulations 2015.

#### IV.1.3) Information about a framework agreement

The procurement involves the establishment of a framework agreement

#### IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

# Section V. Award of contract/concession

A contract/lot is awarded: Yes

## V.2) Award of contract/concession

#### V.2.1) Date of conclusion of the contract

14 April 2025

#### V.2.2) Information about tenders

The contract has been awarded to a group of economic operators: No

#### V.2.3) Name and address of the contractor/concessionaire

Bio Products Laboratory

Dagger Lane, Elstree

Hertfordshire

WD6 3BX

Country

**United Kingdom** 

**NUTS** code

• UK - United Kingdom

The contractor/concessionaire is an SME

No

# V.2.4) Information on value of contract/lot/concession (excluding VAT)

Total value of the contract/lot/concession: £343,908

# **Section VI. Complementary information**

# VI.3) Additional information

The estimated value of the Framework Agreement referred to in Section V.2.4 covers the twenty-four (24) month contract duration and the twenty-four (24) month extension period of the Framework Agreement.

(SC Ref:796275)

### VI.4) Procedures for review

VI.4.1) Review body

**Sheriff Court House** 

27 Chambers Street

Edinburgh

EH1 1LB

Email

edinburgh@scotcourts.gov.uk

Telephone

+44 1312252525

Country

**United Kingdom** 

#### VI.4.3) Review procedure

Precise information on deadline(s) for review procedures

The notification will incorporate a 'standstill period' of a minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which the Authority despatches the VEAT notice and the date on which the Authority proposes to conclude the relevant framework agreement.

The bringing of court proceedings against the authority during the standstill period will automatically continue the prohibition on entering into the framework agreement until the

court proceedings are determined, discontinued or disposed of, or the court, by interim order, brings to an end the prohibition. The remedies that may be awarded by the courts before the framework agreement has been entered into include the setting aside of the decision to award the framework agreement to the winning tenderer.

The bringing of court proceedings against the authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages.